Peripheral
and Central Nervous System Drugs Advisory Committee
May
17, 2006
Slides
Sponsor Presentations
Exelon® (rivastigmine) Introduction and Regulatory Overview, Martina Stuck, PhD,
Novartis Pharmaceuticals Corporation (ppt)
(htm)
The
Neuropathology of Parkinson’s Disease
with Dementia, James
B. Leverenz, MD, University of Washington School of Medicine
(ppt) (htm)
Parkinson’s disease Dementia (PDD)
: A Clinical Perspective, Howard Feldman, MMCM, FRCP (C),University
of British Columbia, Canada (ppt)
(htm)
Clinical Summary, Clive Ballard, MD, University of London
(ppt)
(htm)
Rationale for Indication of Parkinson’s
Disease Dementia (PDD) &
Study Design, Roger Lane, MD, MPH, Novartis
Pharmaceuticals Corporation
(ppt)
(htm)
Express Results, Sibel Tekin, MD,
Novartis Pharmaceuticals Corporation (ppt) (htm)
Benefits-Risk
Assessment, Murat Emre, MD, Istanbul University,
Turkey (ppt) (htm)
Exelon® (rivastigmine) PDD Indication Regulatory Considerations ,
Martina Stuck, PhD, Novartis
Pharmaceuticals Corporation (ppt)
(htm)
Sponsor Supportive
Slides (ppt)
(htm)
Questions (ppt) (htm)